The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The Future of High-Throughput Screening
Open accessAbstract
High-throughput screening (HTS) is a well-established process in lead discovery for pharma and biotech companies and is now also being set up for basic and applied research in academia and some research hospitals. Since its first advent in the early to mid-1990s, the field of HTS has seen not only a continuous change in technology and processes but also an adaptation to various needs in lead discovery. HTS has now evolved into a quite mature discipline of modern drug discovery. Whereas in previous years, much emphasis has been put toward a steady increase in capacity ("quantitative increase") via various strategies in the fields of automation and miniaturization, the past years have seen a steady shift toward higher content and quality ("quality increase") for these biological test systems. Today, many experts in the field see HTS at the crossroads with the need to decide either toward further increase in throughput or more focus toward relevance of biological data. In this article, the authors describe the development of HTS over the past decade and point out their own ideas for future directions of HTS in biomedical research. They predict that the trend toward further miniaturization will slow down with the implementation of 384-well, 1536-well, and 384 low-volume-well plates. The authors predict that, ultimately, each hit-finding strategy will be much more project related, tailor-made, and better integrated into the broader drug discovery efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Origin and evolution of high throughput screening
Pereira, D. A., & Williams, J. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707373 · Cited by 364
Screening in a spirit haunted world
Shoichet, B. K. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.014 · Cited by 276
Critical review of the role of HTS in drug discovery
Macarron, R. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.02.001 · Cited by 241
Evaluating Real-Life High-Throughput Screening Data
Gribbon, P. M., Lyons, R., Laflin, P., Bradley, J., Chambers, C., Williams, B. S., Keighley, W. W., & Sewing, A. (2005) · SLAS DISCOVERY · doi:10.1177/1087057104271957 · Cited by 71
Brandish, P. E., Chiu, C., Schneeweis, J. E., Brandon, N. J., Leech, C. L., Kornienko, O., Scolnick, E. M., Strulovici, B., & Zheng, W. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106288181 · Cited by 59
Case study: impact of technology investment on lead discovery at Bristol–Myers Squibb, 1998–2006
Houston, J. G., Banks, M. N., Binnie, A., Brenner, S. L., O’Connell, J., & Petrillo, E. W. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.004 · Cited by 49
Diversity-Oriented Organic Synthesis and Proteomics
Schreiber, S. L., Nicolaou, K. C., & Davies, K. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00088-1 · Cited by 45
Klumpp, M., Boettcher, A., Becker, D., Meder, G., Blank, J., Leder, L., Forstner, M., Ottl, J., & Mayr, L. M. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106288444 · Cited by 43
Self-citation
Cited by
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Baret, J.-C., Miller, O. J., Taly, V., Ryckelynck, M., El-Harrak, A., Frenz, L., Rick, C., Samuels, M. L., Hutchison, J. B., Agresti, J. J., et al. (2009) · Lab on a Chip · doi:10.1039/b902504a · Cited by 951
Novel trends in high-throughput screening
Mayr, L. M., & Bojanic, D. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.08.004 · Cited by 694
Self-citationAdaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests
Szymański, P., Markowicz, M., & Mikiciuk-Olasik, E. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms13010427 · Cited by 454
3D cell culture opens new dimensions in cell-based assays
Justice, B. A., Badr, N. A., & Felder, R. A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.006 · Cited by 338
Metadata
- Authors
- Mayr, L. M., & Fuerst, P.
- Venue
- SLAS Discovery
- Publisher
- Elsevier BV
- Published
- 2008-07
- Volume
- 13
- Issue
- 6
- Pages
- 443-448
- ISSN
- 2472-5552 (ISSN-L)
- OpenAlex
- W2152917871
- Cited by
- 276
- References
- 11
- FWCI
- 17.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Future of High-Throughput Screening. https://app.cochat.ai/papers/10.1177/1087057108319644
- The paper
- Mayr, L. M., & Fuerst, P. (2008). The Future of High-Throughput Screening. SLAS Discovery. https://doi.org/10.1177/1087057108319644
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.